Biotricity (OTC: BTCY) Expands IP Portfolio with 14 New Patents
As far as innovative companies are concerned, patents play a crucial role, and so is the case with the TAAS (technology as a service) leader Biotricity Inc. (OTC:BTCY). The company was in the news cycle yesterday after it made an announcement about a major expansion in its IP (intellectual property) portfolio with 14 new patents.
Significant Development
In the news release yesterday, Biotricity announced that it had made the breakthrough with more patents. The new patents brought the total number of patents under its control to 15. The company went on to note that the expansion in its IP portfolio was also a demonstration of its strong commitment to the advancement and improvement in patients’ healthcare journeys. The company is involved in providing its services aimed at making diagnostic processes significantly more efficient and streamlined.
Further Information
The company announced that the newest group of patents marked a major breakthrough since it would drive the growth and development of the advanced next-generation medical device from Biotricity. It should be noted that the company also announced that the future of healthcare lay in the ability to manage and monitor patients from their homes.
CEO Quote
“At Biotricity, we believe that the future of patient care lies in the ability to monitor and manage individuals from the comfort of their home.” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “Our solutions deliver actionable data to healthcare providers, facilitating quicker intervention to improve patient outcomes while driving revenue through insurance reimbursement.”
Fundamentals
| P/E Ratio | -0.4600 |
| PEG Ratio | – |
| Price to Book | -0.38 |
| Price to Cash Flow | – |
| Price to Free Cash Flow | – |
| Total Sales (TTM) | 13.27 M |
| Revenue per Share (TTM) | 0.55 |
| Shares Outstanding | 24.913 M |
| Share Float (%) | 14.31 M (57.43%) |
| % Held by Institutions | 0.03 |
